HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: clinchem.2008.117945v1 55/7/1316    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Stutterheim, J. Articles by Tytgat, G. A.M. Search for Related Content PubMed PubMed Citation Articles by Stutterheim, J. Articles by Tytgat, G. A.M.

Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers

¹ Department of Pediatric Oncology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, the Netherlands; ² Department of Immunohematology, Sanquin-AMC Landsteiner Laboratory, Amsterdam, the Netherlands; ³ Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey; ⁴ Department of Pediatric Oncology/Hematology, Sophia Children’s Hospital, Erasmus Medical Center, Rotterdam, the Netherlands; ⁵ Department of Pediatric Oncology and Hematology, Children’s Hospital, University of Cologne, Cologne, Germany; ⁶ Department of Human Genetics, Academic Medical Center, Amsterdam, the Netherlands.

^aAddress correspondence to this author at: Plesmanlaan 125, 1066 CX Amsterdam, the Netherlands. Fax +31–20-5123474; e-mail e.vanderschoot{at}sanquin.nl.

Background: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can be used for initial staging and monitoring therapy response in bone marrow (BM) and peripheral blood (PB). PHOX2B has been identified as a sensitive and specific MRD marker; however, its expression varies between tumors. Therefore, a panel of markers could increase sensitivity.

Methods: To identify additional MRD markers for NB, we selected genes by comparing SAGE (serial analysis of gene expression) libraries of healthy and NB tissues followed by extensive real-time quantitative PCR (RQ-PCR) testing in samples of tumors (n = 56), control BM (n = 51), PB (n = 37), and cell subsets. The additional value of a panel was determined in 222 NB samples from 82 Dutch stage 4 NB patients (54 diagnosis BM samples, 143 BM samples during/after treatment, and 25 PB samples).

Results: We identified 2 panels of specific RQ-PCR markers for MRD detection in NB patients: 1 for analysis of BM samples (PHOX2B, TH, DDC, CHRNA3, and GAP43) and 1 for analysis of PB samples (PHOX2B, TH, DDC, DBH, and CHRNA3). These markers all showed high expression in NB tumors and no or low expression in control BM or PB samples. In patients’ samples, the PHOX2B marker detected most positive samples. In PB samples, however, 3 of 7 PHOX2B-negative samples were positive for 1 or more markers, and in BM examinations during treatment, 7% (6 of 86) of the PHOX2B-negative samples were positive for another marker.

Conclusions: Because of differences in the sensitivities of the markers in BM and PB, we advise the use of 2 different panels to detect MRD in these compartments.

The following articles in journals at HighWire Press have cited this article:

				V. F. Viprey and S. A. Burchill Gene Expression Profiling for Discovery of Novel Markers of Minimal Disease Clin. Cancer Res., November 1, 2009; 15(21): 6742 - 6742. [Full Text] [PDF]

				B. Kagedal Detecting Minimal Residual Disease in Neuroblastoma: Still a Ways to Go Clin. Chem., July 1, 2009; 55(7): 1268 - 1270. [Full Text] [PDF]